Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced ...

Received approval for first purchase in France. VIVO is now active in six European countries. Completed enrollment of Phase I LockeT study in excess of 100 patients. Received Institutional Review ...

Expands Global Footprint to 15 CountriesFORT MILL, S.C., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing ...

Catheter Precision, Inc., a US medical device company specializing in cardiac electrophysiology, will attend the 13th International Symposium on Left Atrial Appendage (ISLAA) in Austin, Texas on ...

This data was produced from a multi-center study that enrolled 125 patients. The data demonstrates that VIVO was over 94% accurate, assisted physicians in determining workflow when used pre-procedure, ...

FORT MILL, SC / ACCESSWIRE / November 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced it ...

FORT MILL, SC / ACCESSWIRE / April 24, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) ($VTAK), a leading MedTech company specializing in innovative products for ...